185 related articles for article (PubMed ID: 20039391)
1. The solubility-permeability interplay in using cyclodextrins as pharmaceutical solubilizers: mechanistic modeling and application to progesterone.
Dahan A; Miller JM; Hoffman A; Amidon GE; Amidon GL
J Pharm Sci; 2010 Jun; 99(6):2739-49. PubMed ID: 20039391
[TBL] [Abstract][Full Text] [Related]
2. The solubility-permeability interplay: mechanistic modeling and predictive application of the impact of micellar solubilization on intestinal permeation.
Miller JM; Beig A; Krieg BJ; Carr RA; Borchardt TB; Amidon GE; Amidon GL; Dahan A
Mol Pharm; 2011 Oct; 8(5):1848-56. PubMed ID: 21800883
[TBL] [Abstract][Full Text] [Related]
3. The solubility-permeability interplay when using cosolvents for solubilization: revising the way we use solubility-enabling formulations.
Miller JM; Beig A; Carr RA; Webster GK; Dahan A
Mol Pharm; 2012 Mar; 9(3):581-90. PubMed ID: 22280478
[TBL] [Abstract][Full Text] [Related]
4. The interaction of nifedipine with selected cyclodextrins and the subsequent solubility-permeability trade-off.
Beig A; Miller JM; Dahan A
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):1293-9. PubMed ID: 23770429
[TBL] [Abstract][Full Text] [Related]
5. Predicting the solubility-permeability interplay when using cyclodextrins in solubility-enabling formulations: model validation.
Miller JM; Dahan A
Int J Pharm; 2012 Jul; 430(1-2):388-91. PubMed ID: 22465550
[TBL] [Abstract][Full Text] [Related]
6. The Solubility-Permeability Trade-Off of Progesterone With Cyclodextrins Under Physiological Conditions: Experimental Observations and Computer Simulations.
Sun L; Zhang B; Sun J
J Pharm Sci; 2018 Jan; 107(1):488-494. PubMed ID: 29031956
[TBL] [Abstract][Full Text] [Related]
7. Toward Successful Cyclodextrin Based Solubility-Enabling Formulations for Oral Delivery of Lipophilic Drugs: Solubility-Permeability Trade-Off, Biorelevant Dissolution, and the Unstirred Water Layer.
Fine-Shamir N; Beig A; Zur M; Lindley D; Miller JM; Dahan A
Mol Pharm; 2017 Jun; 14(6):2138-2146. PubMed ID: 28505451
[TBL] [Abstract][Full Text] [Related]
8. Oral delivery of lipophilic drugs: the tradeoff between solubility increase and permeability decrease when using cyclodextrin-based formulations.
Beig A; Agbaria R; Dahan A
PLoS One; 2013; 8(7):e68237. PubMed ID: 23874557
[TBL] [Abstract][Full Text] [Related]
9. A win-win solution in oral delivery of lipophilic drugs: supersaturation via amorphous solid dispersions increases apparent solubility without sacrifice of intestinal membrane permeability.
Miller JM; Beig A; Carr RA; Spence JK; Dahan A
Mol Pharm; 2012 Jul; 9(7):2009-16. PubMed ID: 22632106
[TBL] [Abstract][Full Text] [Related]
10. Common solubilizers to estimate the Caco-2 transport of poorly water-soluble drugs.
Takahashi Y; Kondo H; Yasuda T; Watanabe T; Kobayashi S; Yokohama S
Int J Pharm; 2002 Oct; 246(1-2):85-94. PubMed ID: 12270611
[TBL] [Abstract][Full Text] [Related]
11. Pharmaceutical applications of cyclodextrins: effects on drug permeation through biological membranes.
Loftsson T; Brewster ME
J Pharm Pharmacol; 2011 Sep; 63(9):1119-35. PubMed ID: 21827484
[TBL] [Abstract][Full Text] [Related]
12. Accounting for the solubility-permeability interplay in oral formulation development for poor water solubility drugs: the effect of PEG-400 on carbamazepine absorption.
Beig A; Miller JM; Dahan A
Eur J Pharm Biopharm; 2012 Jun; 81(2):386-91. PubMed ID: 22387337
[TBL] [Abstract][Full Text] [Related]
13. In silico predictions of gastrointestinal drug absorption in pharmaceutical product development: application of the mechanistic absorption model GI-Sim.
Sjögren E; Westergren J; Grant I; Hanisch G; Lindfors L; Lennernäs H; Abrahamsson B; Tannergren C
Eur J Pharm Sci; 2013 Jul; 49(4):679-98. PubMed ID: 23727464
[TBL] [Abstract][Full Text] [Related]
14. The use of captisol (SBE7-β-CD) in oral solubility-enabling formulations: Comparison to HPβCD and the solubility-permeability interplay.
Beig A; Agbaria R; Dahan A
Eur J Pharm Sci; 2015 Sep; 77():73-8. PubMed ID: 26006306
[TBL] [Abstract][Full Text] [Related]
15. Effects of cyclodextrins on drug delivery through biological membranes.
Loftsson T; Vogensen SB; Brewster ME; Konrádsdóttir F
J Pharm Sci; 2007 Oct; 96(10):2532-46. PubMed ID: 17630644
[TBL] [Abstract][Full Text] [Related]
16. Absorption-excipient-pH classification gradient maps: sparingly soluble drugs and the pH partition hypothesis.
Avdeef A; Kansy M; Bendels S; Tsinman K
Eur J Pharm Sci; 2008 Jan; 33(1):29-41. PubMed ID: 17983735
[TBL] [Abstract][Full Text] [Related]
17. Drug permeation through biomembranes: cyclodextrins and the unstirred water layer.
Loftsson T
Pharmazie; 2012 May; 67(5):363-70. PubMed ID: 22764564
[TBL] [Abstract][Full Text] [Related]
18. PAMPA--a drug absorption in vitro model 7. Comparing rat in situ, Caco-2, and PAMPA permeability of fluoroquinolones.
Bermejo M; Avdeef A; Ruiz A; Nalda R; Ruell JA; Tsinman O; González I; Fernández C; Sánchez G; Garrigues TM; Merino V
Eur J Pharm Sci; 2004 Mar; 21(4):429-41. PubMed ID: 14998573
[TBL] [Abstract][Full Text] [Related]
19. Methacrylate-Copolymer Eudragit EPO as a Solubility-Enabling Excipient for Anionic Drugs: Investigation of Drug Solubility, Intestinal Permeability, and Their Interplay.
Fine-Shamir N; Dahan A
Mol Pharm; 2019 Jul; 16(7):2884-2891. PubMed ID: 31120762
[TBL] [Abstract][Full Text] [Related]
20. Effect of β-cyclodextrin derivatives on the diosgenin absorption in Caco-2 cell monolayer and rats.
Okawara M; Tokudome Y; Todo H; Sugibayashi K; Hashimoto F
Biol Pharm Bull; 2014; 37(1):54-9. PubMed ID: 24389481
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
